S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Bank Accounts: Frozen! (Ad)
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
Urgent Warning (Ad)
Travel disruption hits Germany on eve of transport strike
Biden's pick to lead FAA withdraws amid shaky Senate support
Bank Accounts: Frozen! (Ad)
Berlin climate proposal fails to get enough yes votes to win
Adele extends Las Vegas residency, plans concert film
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Bank Accounts: Frozen! (Ad)
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
Urgent Warning (Ad)
Travel disruption hits Germany on eve of transport strike
Biden's pick to lead FAA withdraws amid shaky Senate support
Bank Accounts: Frozen! (Ad)
Berlin climate proposal fails to get enough yes votes to win
Adele extends Las Vegas residency, plans concert film
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Bank Accounts: Frozen! (Ad)
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
Urgent Warning (Ad)
Travel disruption hits Germany on eve of transport strike
Biden's pick to lead FAA withdraws amid shaky Senate support
Bank Accounts: Frozen! (Ad)
Berlin climate proposal fails to get enough yes votes to win
Adele extends Las Vegas residency, plans concert film
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Bank Accounts: Frozen! (Ad)
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
Urgent Warning (Ad)
Travel disruption hits Germany on eve of transport strike
Biden's pick to lead FAA withdraws amid shaky Senate support
Bank Accounts: Frozen! (Ad)
Berlin climate proposal fails to get enough yes votes to win
Adele extends Las Vegas residency, plans concert film
NASDAQ:MCRB

Seres Therapeutics - MCRB Stock Forecast, Price & News

$5.69
+0.02 (+0.35%)
(As of 03/24/2023 12:00 AM ET)
Add
Compare
Today's Range
$5.49
$5.71
50-Day Range
$4.95
$6.09
52-Week Range
$2.50
$9.49
Volume
863,994 shs
Average Volume
1.25 million shs
Market Capitalization
$717.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.25

Seres Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
185.6% Upside
$16.25 Price Target
Short Interest
Bearish
6.20% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.14
Upright™ Environmental Score
News Sentiment
1.06mentions of Seres Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.08) to ($1.62) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.17 out of 5 stars

Medical Sector

422nd out of 1,005 stocks

Pharmaceutical Preparations Industry

194th out of 486 stocks


MCRB stock logo

About Seres Therapeutics (NASDAQ:MCRB) Stock

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Receive MCRB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Seres Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MCRB Stock News Headlines

Seres Therapeutics (NASDAQ:MCRB) Shares Down 4.9%
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Where Seres Therapeutics Stands With Analysts
Q4 2022 Seres Therapeutics Inc Earnings Call
Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
Seres Therapeutics Earnings Preview
Seres Therapeutics
Seres Gets Closer To Good Times
See More Headlines
Receive MCRB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Seres Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MCRB Company Calendar

Last Earnings
11/10/2021
Today
3/26/2023
Next Earnings (Estimated)
5/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MCRB
Fax
N/A
Employees
333
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$16.25
High Stock Price Forecast
$25.00
Low Stock Price Forecast
$12.00
Forecasted Upside/Downside
+185.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-250,160,000.00
Net Margins
-3,509.50%
Pretax Margin
-3,509.50%

Debt

Sales & Book Value

Annual Sales
$7.13 million
Book Value
$0.09 per share

Miscellaneous

Free Float
120,781,000
Market Cap
$717.40 million
Optionable
Optionable
Beta
2.70

Key Executives

  • Eric D. Shaff
    President, Chief Executive Officer & Director
  • Marcus Chapman
    Senior Vice President-Operations
  • David A. Arkowitz
    EVP, Chief Financial & Accounting Officer
  • Matthew R. Henn
    Chief Scientific Officer & Executive VP
  • Barbara McGovern
    Vice President-Medical Affairs













MCRB Stock - Frequently Asked Questions

Should I buy or sell Seres Therapeutics stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Seres Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MCRB shares.
View MCRB analyst ratings
or view top-rated stocks.

What is Seres Therapeutics' stock price forecast for 2023?

5 brokerages have issued 12-month price targets for Seres Therapeutics' shares. Their MCRB share price forecasts range from $12.00 to $25.00. On average, they anticipate the company's stock price to reach $16.25 in the next twelve months. This suggests a possible upside of 185.6% from the stock's current price.
View analysts price targets for MCRB
or view top-rated stocks among Wall Street analysts.

How have MCRB shares performed in 2023?

Seres Therapeutics' stock was trading at $5.60 at the beginning of the year. Since then, MCRB shares have increased by 1.6% and is now trading at $5.69.
View the best growth stocks for 2023 here
.

When is Seres Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our MCRB earnings forecast
.

How were Seres Therapeutics' earnings last quarter?

Seres Therapeutics, Inc. (NASDAQ:MCRB) posted its earnings results on Wednesday, November, 10th. The biotechnology company reported $0.72 earnings per share for the quarter, beating the consensus estimate of ($0.47) by $1.19. The biotechnology company earned $126.73 million during the quarter, compared to the consensus estimate of $7.12 million. Seres Therapeutics had a negative trailing twelve-month return on equity of 548.64% and a negative net margin of 3,509.50%. During the same period last year, the firm earned ($0.36) earnings per share.

What other stocks do shareholders of Seres Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Seres Therapeutics investors own include OPKO Health (OPK), TherapeuticsMD (TXMD), Juno Therapeutics (JUNO), NVIDIA (NVDA), Walt Disney (DIS), Alibaba Group (BABA), Novavax (NVAX), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX) and Gilead Sciences (GILD).

When did Seres Therapeutics IPO?

(MCRB) raised $101 million in an initial public offering (IPO) on Friday, June 26th 2015. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and BofA Merrill Lynch acted as the underwriters for the IPO and Leerink Partners and Canaccord Genuity were co-managers.

What is Seres Therapeutics' stock symbol?

Seres Therapeutics trades on the NASDAQ under the ticker symbol "MCRB."

Who are Seres Therapeutics' major shareholders?

Seres Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Eversept Partners LP (1.77%), Geode Capital Management LLC (1.28%), Point72 Asset Management L.P. (0.56%), Jennison Associates LLC (0.54%), Charles Schwab Investment Management Inc. (0.51%) and JPMorgan Chase & Co. (0.49%). Insiders that own company stock include David S Ege and Health Ltp Fund Ge Nutritional.
View institutional ownership trends
.

How do I buy shares of Seres Therapeutics?

Shares of MCRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Seres Therapeutics' stock price today?

One share of MCRB stock can currently be purchased for approximately $5.69.

How much money does Seres Therapeutics make?

Seres Therapeutics (NASDAQ:MCRB) has a market capitalization of $717.40 million and generates $7.13 million in revenue each year. The biotechnology company earns $-250,160,000.00 in net income (profit) each year or ($2.34) on an earnings per share basis.

How many employees does Seres Therapeutics have?

The company employs 333 workers across the globe.

How can I contact Seres Therapeutics?

Seres Therapeutics' mailing address is 200 SIDNEY STREET - 4TH FLOOR, CAMBRIDGE MA, 02139. The official website for the company is www.serestherapeutics.com. The biotechnology company can be reached via phone at (617) 945-9626 or via email at ctanzi@serestherapeutics.com.

This page (NASDAQ:MCRB) was last updated on 3/26/2023 by MarketBeat.com Staff